Abstract
INTRODUCTION
Heart failure (HF) remains a major risk of morbidity and mortality [1] . While the prevalence for HF with preserved ejection fraction increases, prevalence of HF with decreased ejection fraction decreased during past years [2] . This is partially due to increased use of mechanical assist devices in the therapy of end-stage HF.
In fact, in the time of diminishing supply of available organs, mechanical assist devices are becoming more crucial in the therapy of end-stage HF. In recent years, the use of these devices especially left ventricular assist devices (LVAD) has considerably increased [3, 4] . For most patients, this is not only the only chance for survival but it also has an enormous impact on the quality of life [5] . In the current clinical practice, LVADimplantation is indicated as bridge to transplant, bridge to recovery or as a destination therapy [4, 6] . Since the first successful use of mechanical assist device by M.E. DeBakey in 1966 [7] , clinicians and scientists are aiming to understand its implication on the cardiac tissue, its anatomical and molecular alterations, the impact on the HF and putative remodelling. A major effect of LVAD is the mechanical unloading of the heart restoring the cardiac output and hence improving organ perfusion. The term 'reverse remodelling' emerged over the past years when discussing the effects of LVAD on the cardiac tissue. It is a broad term describing the alterations of the myocardial tissue on the molecular and structural level leading to an actual improvement [4, 5] . This process happens on several levels of myocardial molecular constructs involving alterations in gene expression, proteome modifications as well as neurohormonal and immunological factors. LVAD-induced alterations of myocardial gene expression have been in the focus of several studies on the mRNA level (e.g. [4, [8] [9] [10] but less studies investigated gene expression products on the protein level [11] . The impact of LVAD on biological changes and remodelling offers a vast field of research and new discoveries. Our study focuses on proteome biology upon LVAD-therapy. This is an explorative study aiming to unravel LVAD-induced proteome alterations in order to better grasp the consequences of mechanical unloading. We analysed left ventricular cardiac tissue pre-and post-LVAD implantation of 11 patients with dilate cardiomyopathy (Fig. 1 ) using quantitative proteomics (Fig. 2) .
MATERIALS AND METHODS

Ethics statement
The study was approved by the Ethics Committee of the University Medical Center Freiburg, (498/13). Before study inclusion, all patient data were pseudonymized. Patients gave written informed consent for the use of their tissues for research purposes.
Patients
Eleven adult patients with dilated, non-ischaemic cardiomyopathy were included. Previous surgery, coronary artery disease, diabetes and known myopathy were exclusion criteria. Clinical characteristics are summarized in Table 1 .
Tissue collection, sample preparation and mass spectrometric analysis All patients had samples taken both at the time of LVAD implantation ('pre-LVAD') and at the time of heart transplantation ('post-LVAD'). Tissues were immediately frozen and cryopreserved at -80 C. During LVAD insertion, the apical resection material from the inflow cannula placement was taken. The 'post-LVAD' sample was taken from the explanted recipient heart from the left ventricular free lateral wall.
Tissue sections for analysis were cut from frozen tissue. Myocardial tissue (150-200 mg) was homogenized in lysis buffer (2 M guanidine hydrochloride in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5) with the help of a Precellys tissue homogenizer (Peqlab) using 2.8 mm stainless steel beads. Further processing steps were performed as described [12] including trypsination and differential dimethylation using stable isotope variants of formaldehyde to distinguish the different samples. Patientmatched pre-and post-LVAD samples were mixed, pre-fractionated by strong-exchange chromatography and analysed by liquid chromatography-tandem mass spectrometry as described [13] .
Data analysis
MS data was analysed by MaxQuant [14] version 1.5.28 with the Uniprot human database downloaded on November 2015, counting 20 193 reviewed entries. Initial search tolerance was 20 ppm, main search tolerance was 6 ppm for precursors and 20 ppm for fragment ions. Fixed modification was cysteine carbamidomethylation without variable modifications. Tryptic cleavage specificity with no missed cleavages was used. A minimum of 2 peptides was required for protein identification. The false discovery rate was 0.01 for peptide and protein identifications. For quantitative comparison, we used a labelling scheme based on multiplicity 2: dimethLys0/dimethNter0 (light label); dimethLys6/ dimethNter6 (heavy label) with a minimum of 2 ratio counts per protein. A second search with identical parameters but allowing for semi-tryptic peptides was performed to identify protease cleavage sites. These results were only considered on the peptide level. Only proteins and peptides identified in at least 6/11 patient cases were further analysed. Ratios were log 2 transformed and normalized by centring.
Immunoblotting
Western-blot analysis was performed as described elsewhere [12] using 30 mg of cardiac, left ventricular tissue lysate. Primary antibody was anti-periostin (Abcam ab14041, 1:1000 dilution), secondary antibody was anti-rabbit (BioRad 172-1019, 1:3000 solution).
Histological analysis
For 9 of the 11 patients, there was sufficient tissue to perform histological analyses. Tissue specimens were formalin fixed, paraffin embedded, serial sliced (3 mm each slice) and stained for haematoxylin-eosin and sirius red according to routine protocols. Fibrosis and inflammation were evaluated in vision fields of 400-fold magnification by 2 experienced pathologists, blinded for patient data and clinical outcome. Myocardial fibrosis was 
Statistical analysis
Statistical analysis using linear models for microarray data (limma) [15] was used. Following the calculation of a moderatedt-test, proteins with a P-value < 0.05 and a quantitative alteration >50% (either increase or decrease) were considered as being significantly affected.
RESULTS
Global impact of left ventricular assist device implantation on the cardiac proteome
Liquid chromatography-tandem mass spectrometry analysis identified and quantified 1444-2440 proteins in each of the 11 patient-matched samples. We focused on proteins that were found in at least 6 cases, resulting in a final set 1703 proteins for further analyses. As highlighted in Fig. 3A , the 11 cases display comparable, yet distinct distributions of the quantitative alterations between the pre-and post-LVAD proteomes.
To identify proteins that significantly differ in their abundance pre-or post-LVAD, we employed limma statistics [15] . We chose the following criteria to distinguish significantly regulated proteins: (i) limma moderated P-value < 0.05 and (ii) average increase or decrease in abundance by more than 50% [log 2 (post-LVAD/ pre-LVAD) >0.58 for increase; log 2 (post-LVAD/pre-LVAD) < -0.58 for decrease]. These criteria highlight 56 down-regulated proteins post-LVAD and 43 up-regulated proteins post-LVAD (Supplementary Material, Table S1 ).
Previous proteomic studies found decreased post-LVAD levels of a-1-antichymotrypsin (synonym is serpin A3, a secreted protease inhibitor) [11, 16] , thus defining a-1-antichymotrypsin as a suitable benchmark to validate our present dataset. We observed a more than 2-fold [log 2 (post-LVAD/pre-LVAD) = -1.1] downregulation of a-1-antichymotrypsin post-LVAD (P < 0.01). This finding further strengthens a prominent role of a-1-antichymotrypsin in the proteome biology upon LVAD implantation as well as underlining reliability and robustness of the present dataset.
Biological processes and pathways affected by left ventricular assist device implantation
In order to identify clusters of co-regulated functionally related proteins, we used the gene ontology protein annotation system, with a focus on 'biological processes'. Enrichment analysis aimed to identify clusters with a P-value < 0.01 and including at least 4 significantly affected proteins. Additional manual data mining distilled 4 clusters of down-regulated proteins and 3 clusters of upregulated proteins (Fig. 4) . The clusters of down-regulated proteins comprise proteins belonging to:
• Matricellular proteins and proteoglycans • Transforming growth factor (TGF)b signalling • Complement system • Cardiac neurohormones.
The clusters of up-regulated proteins comprise proteins belonging to:
• (Innate) immune system • Metabolism • Protein synthesis and secretion.
Decrease post-LVAD: matricellular proteins
This cluster includes 7 proteins such as fibulin-2 and -3, fibromodulin, versican, thrombospondin-5 and periostin. Stansfield et al. [17] also reported significantly reduced periostin levels post-LVAD as probed by immuno-blotting. In our case, we found very good peptide coverage of periostin for every sample (Fig. 5 ). Similar to Stansfield et al. [17] , we observe some inter-patient heterogeneity with regards to the post-LVAD decrease of periostin (Fig. 5) . We selected a case of reduced periostin levels post-LVAD (Patient #6) and a case of increased periostin levels post-LVAD (Patient #4) for immunoblotting analysis of periostin. In both cases, our mass spectrometry-based protein quantitation was corroborated (Supplementary Material, Fig. S1 ). Furthermore, we probed the extent of fibrosis by sirius red staining (Supplementary Material, Fig. S2A-C) . Both in the pre-LVAD and in the post-LVAD situation notable levels of fibrosis were present. However, no statistically significant difference was found (P > 0.3 for both analyses, two-sided, paired Student t-test).
Decrease post-left ventricular assist device: transforming growth factorb signalling
This cluster comprises 2 proteins that play accessory, yet crucial roles in TGFb signalling: latent-TGFb-binding protein-1 and -2. TGFb itself has not been identified. Latent-TGFb-binding protein-4 was also found to be reduced post-LVAD (P < 0.05), however the extent of its reduction (less than 50%) failed to meet our selection criteria for affected proteins.
Decrease post-left ventricular assist device: complement system
This cluster contains 6 proteins of the complement system. Furthermore, we probed the extent of immune infiltration by haematoxylin-eosin-staining (Supplementary Material, Fig. S3A-D) . Both in the pre-LVAD and in the post-LVAD situation, some immune infiltration was notable. However, no statistically significant difference was found (P > 0.4 for both analyses, two-sided, paired Student t-test).
Decrease post-left ventricular assist device: cardiac peptide hormones
This cluster comprises 2 proteins, namely natriuretic peptides A (synonym is atrial natriuretic peptide) and angiotensinogen. Due to their short peptide length (1-9 residues, including a tryptic cleavage site), the various angiotensin species escape identification by our global proteomic approach, which also involves trypsination. We identified and quantified the angiotensin precursor angiotensinogen, which comprises >450 residues.
Increase post-left ventricular assist device: (innate) immune system
This cluster comprises 5 proteins and enzymes, which share functionality or regulatory roles within the (innate) immune system. Members include myeloperoxidase, macrophage migration inhibitory factor, cathepsin G, C-X-C motif chemokine 7 and a neutrophil defensin. As outlined above, we did not observe a statistically significant difference regarding immune infiltration.
Increase post-left ventricular assist device: diverse metabolic proteins
This cluster unites a set of 6 metabolic proteins, some of which are located in the mitochondrium (e.g. glutaryl-CoA dehydrogenase, propionyl-CoA carboxylase) while others are rather cytoplasmic (e.g. beta-enolase, fructose-bisphosphate aldolase).
Increase post-left ventricular assist device: ribosomal proteins
This cluster is composed of 5 proteins including 4 ribosomal proteins and 1 component of the signal recognition particle system. The cluster is suggestive of augmented protein synthesis post-LVAD via elevated ribosome biogenesis. Ribosome biogenesis post-LVAD has been scarcely studied with the notable exception of 1 report that corroborated augmented protein synthesis and elevated ribosome biogenesis upon LVAD therapy [18] . 
Left ventricular assist device therapy affects endogenous proteolytic processing in the myocardium
We reanalysed our data and allowed for peptide sequences to possess a non-tryptic amino-or carboxy-terminus (so-called 'semitryptic peptides'), which represent proteolytic processing in the myocardium prior to sample processing for proteomic analysis (Fig.  6A ). This approach identified and quantified 693 protein termini. Similar to the protein-level analysis, we employed limma statistics to delineate significantly affected sites of proteolytic processing (Fig. 6B ). Criteria were: (i) limma moderated P-value < 0.05 and (ii) average increase or decrease in abundance by more than 50% [log 2 (post-LVAD/pre-LVAD) >0.58 for increase; log 2 (post-LVAD/pre-LVAD) < -0.58 for decrease]. These criteria identify 33 cleavage sites that are down-regulated post-LVAD and 74 cleavage sites that are up-regulated post-LVAD. The data on proteolytically generated protein N-termini is summarized in Supplementary Material, Table  S2 . In Fig. 6C , we illustrate several examples of proteolytic cleavage sites that are significantly affected upon LVAD therapy.
DISCUSSION
We successfully profiled the myocardial proteome pre-and post-LVAD in a patient-matched manner and present evidence that LVAD therapy yields remodelling on the myocardial proteome level.
Our study design aimed for patient-matched comparisons of the left ventricular proteome pre-and post-LVAD. The pronounced heterogeneity of the proteomic response to LVAD therapy renders a patient-matched perspective particularly important. If reduced to a solely group-wise comparison, many proteomic differences might remain blurred. Our study design could not unambiguously include a third group of non-patient matched healthy heart samples. Consequently, we can observe LVAD-induced proteome alterations but in most cases-unless further studies exist-we cannot clearly state whether these alterations are in the direction of a healthy heart proteome.
Pre-LVAD samples were harvested directly from the left ventricular apex while post-LVAD sample was harvested from the left ventricular free lateral wall of the explanted heart. We consider it likely that the minor difference in localization has only a negligible effect on proteome alteration since mechanical unloading affects the entire left ventricle.
Many proteomic studies disregard the necessity of multiple testing corrections. We employed limma statistics for this purpose. To discern truly affected proteins from false positive discoveries, we chose parameters (e.g. P-value cut-off), which we previously evaluated using real-protein IDs together with randomized quantitative alterations.
Proteins such as periostin or versican are often studied in the context of fibrosis. However, they represent a different protein class than prototypical extracellular matrix (ECM) proteins such as highly cross-linked, largely insoluble fibrous collagens. Matricellular proteins rather constitute a non-structural, functional component of the extracellular 'matrisome' [19] . In our study, we identified classical markers of fibrosis (e.g. Collagens I and IV), however these were not differentially regulated (P > 0.10 for Collagens I and IV; quantitative alteration <50%). This is in line with the sirius red staining results. Generally, the impact of mechanical unloading on cardiac fibrosis remains a controversial issue with different published reports supporting either an increase or decrease post-LVAD fibrosis (e.g. reviewed in [4] ).
The impact of LVAD therapy on matricellular proteins highlights the LVAD-induced matrisome remodelling. In this regard it is worth noting that the exact role(s) of the various matricellular proteins in cardiac biology remain a controversial topic. Kuhn et al. [20] suggested that 'Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair' while a later study Lorts et al. [21] disputed these findings. Stansfield et al. [17] corroborate our finding of reduced levels of tissue-resident periostin post-LVAD. Generally, our findings suggest that the non-collagenous cardiac matrisome warrants further investigation both on the levels of expression and functionality.
TGFb is a key component of cardiac remodelling [22] and TGFb signalling regulates the expression of matricellular proteins such as periostin [22] . This situation is also represented in the present data: in Fig. 7 , we display the individual alterations post-LVAD for the proteins members of the different clusters. In cases #4 and, to a lesser extent, #9, the decrease of TGFb signalling is either absent or less pronounced correlating with a missing decrease of matricellular proteins.
Additionally, our data demonstrate a prominent post-LVAD decrease of complement proteins in the myocardial tissue. Three independent studies have demonstrated a post-LVAD decrease of circulating complement to levels below the actual pre-LVAD status [23] [24] [25] . Given the association between complement and cardiomyopathy, including a rather damaging role of the complement system, decreased post-LVAD levels of complement may point to a beneficial effect of LVAD therapy.
A post-LVAD decrease of cardiac peptide hormones such as natriuretic peptide A and angiotensin has been reported by numerous studies and can, by now, be regarded as a molecular hallmark of LVAD therapy [4] . Most studies on the angiotensin system inherently focused on the short, bioactive angiotensin peptides rather than the long angiotensinogen precursor. While the short angiotensin peptides are non-amenable to our proteomic approach, we identified a post-LVAD decrease of angiotensinogen; thus strengthening the aspect of a post-LVAD decrease of cardiac peptide hormones and their precursors.
Regarding the slight increase of immune-related proteins, a transcriptomic study on blood of LVAD patients highlighted elevated expression of immune response genes after 180 days of LVAD therapy [26] . A further study likewise highlighted an augmented inflammatory response upon long-term (i.e. several months) LVAD therapy [27] . It has been discussed whether the implanted device contributes to this inflammatory response [27] . In our study however, we did not find substantially elevated immune infiltration post-LVAD.
A slightly positive impact of LVAD therapy on cardiac metabolism is presently discussed [4] . Beta-enolase and fructose-bisphosphate aldolase both act in the glycolysis pathway; however further glycolytic enzymes such as hexokinase do not display differential regulation post-LVAD (Supplementary Material, Table S1 ). Likewise, there was no evidence for a concomitant, significant increase in enzymes that play a role in oxidative phosphorylation. A clear picture of the 'metabolic proteome' post-LVAD failed to emerge.
We further analysed the proteomic data for proteolytically truncated protein termini as an indication of altered proteolytic processing post-LVAD. Our study highlighted (amongst others) differential processing of apolipoprotein-1, PDZ and LIM domain protein 1, cystatin-B and phosphohistidine phosphatase (Fig. 6C) . Apolipoprotein-1 requires activation of its proform by removal of a short N-terminal propeptide. This step is significantly decreased post-LVAD. PDZ and LIM domain protein 1 is a cytoskeletal protein. We identify a cleavage between the ZM and LIM domains, which is increased upon LVAD therapy; resulting in domain separation. Cystatin-B is a cytosolic inhibitor of cysteine cathepsin proteases to capture their activity upon lysosomal leakage. LVAD therapy down-regulates a cleavage close to the N-terminus of cystatin-B, positioned in the reactive site of cystatin-B [28] , thus deactivating its inhibitory potential. Further, we identified a cleavage site close to the C-terminus of phosphohistidine phosphatase, which likely impairs its biological activity by affecting the substrate binding site. The proteolytic cleavage is increased upon LVAD therapy.
Our findings show a strong impact of LVAD therapy on the left ventricular proteome with prominent inter-patient heterogeneity. Many of our proteomic findings are corroborated by independent studies, thus strengthening the validity of the present data. Reduced myocardial levels of a-1-antichymotrypsin and natriuretic peptides are emerging as molecular hallmarks of LVAD therapy. Furthermore, our data highlights altered myocardial proteolysis with subsequent effects on protein functionality.
